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Abstract
The prevalence of preexisting immunity to adenoviruses in the majority of the human population might adversely impact
the development of adaptive immune responses against adenovirus vector-based vaccines. To address this issue, we
primed BALB/c mice either intranasally (i.n.) or intramuscularly (i.m.) with varying doses of wild type (WT) human adenovirus
subtype 5 (HAd5). Following the development of immunity against HAd5, we immunized animals via the i.n. or i.m. route of
inoculation with a HAd vector (HAd-HA-NP) expressing the hemagglutinin (HA) and nucleoprotein (NP) of A/Vietnam/1203/
04 (H5N1) influenza virus. The immunogenicity and protection results suggest that low levels of vector immunity (,520
virus-neutralization titer) induced by priming mice with up to 10
7 plaque forming units (p.f.u.) of HAd-WT did not adversely
impact the protective efficacy of the vaccine. Furthermore, high levels of vector immunity (approximately 1500 virus-
neutralization titer) induced by priming mice with 10
8 p.f.u. of HAd-WT were overcome by either increasing the vaccine
dose or using alternate routes of vaccination. A further increase in the priming dose to 10
9 p.f.u. allowed only partial
protection. These results suggest possible strategies to overcome the variable levels of human immunity against
adenoviruses, leading to better utilization of HAd vector-based vaccines.
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Introduction
Adenoviruses (Ad) possess several attributes that make them
suitable candidates for vaccine vectors [1,2]. Ad exert an adjuvant-
like effect by stimulating the innate immune system through both
Toll-like receptor (TLR)-dependent and TLR-independent path-
ways [3,4]. The effectiveness of Ad vector-based vaccines against
many infectious diseases, including measles, severe acute respira-
tory syndrome (SARS), human immunodeficiency virus (HIV),
hepatitis B and Ebola has been evaluated in animal models and
clinical trials in humans [5–9]. Previously, we and others have
explored the potential of a human Ad serotype 5 (HAd5) vector-
based vaccine strategy for H5N1 influenza [10–12]. Our
immunogenicity and protective efficacy studies demonstrated that
Ad vector-based vaccines provide complete protection against
challenge with homologous and antigenically distinct strains of
influenza viruses in a mouse model [11].
There is a high incidence of Ad infections in the general
population due to the circulation of more than fifty Ad serotypes.
Their ubiquitous nature results in the development of Ad-specific
neutralizing antibodies, popularly known as ‘preexisting vector
immunity’ in the majority of the individuals [13–15]. Ad-
neutralizing antibodies inhibit the vector extracellularly, while
Ad-specific CD8+ T cells destroy vector expressing cells [16,17]
thereby adversely impacting the duration and levels of transgene
expression. Experimental studies in animal models have shown
that in the presence of extremely high levels of Ad-neutralizing
antibodies, there is a significant inhibition in the development of
immunogen-specific immune responses [18]. A comprehensive
analysis of Ad seroprevalence found that HAd5 neutralizing
antibody titers in the study’s participants varied by geographic
location and ranged from 18 to 4690 [19]. According to this study,
26% of the participants had titers below 200, 40% had titers below
1000, and 20% exhibited titers greater than 1000. These studies
have underscored the need to further evaluate the role of vector
immunity in inhibiting the immunogenicity and efficacy of HAd
vector-based vaccines.
To determine the level of vector immunity that can be tolerated
without significantly affecting the vaccine efficacy, we primed
groups of mice with varying doses of wild type (WT) HAd5 via
intranasal (i.n.) or intramuscular (i.m.) route of inoculation to
generate different levels of HAd5-neutralizing antibody titers.
After the development of HAd5-specific immunity, HAd-primed
mice were immunized i.n. or i.m. with a low or high dose of a HAd
vector (HAd-HA-NP) carrying the hemagglutinin (HA) and
nucleoprotein (NP) genes of the A/Vietnam/1203/04 (H5N1)
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33428influenza virus. We also assessed if we could overcome vector
immunity by increasing the vaccine dose and changing the route
of immunization. Our results suggest that a high level (up to a
neutralization titer of 2240) of vector immunity can be tolerated or
effectively overcome by increasing the vaccine dose or using
alternate routes of vaccination.
Results
Generation and characterization of HAd vector expressing
HA and NP of H5N1 influenza virus (HAd-HA-NP)
The full coding region of HA under the control of the
cytomegalovirus (CMV) immediate early promoter and bovine
growth hormone (BGH) polyadenylation signal (polyA) and full
length coding region of NP gene of the A/Vietnam/1203/04 virus
under the control of the murine CMV promoter and the simian
virus 40 (SV40) polyA were inserted into early region 1 (E1) of the
HAd genome using the Cre-recombinase-mediated site-specific
recombination system [20]. Both genes in HAd-HA-NP were in
the E1-parallel orientation. The recombinant vector, HAd-HA-
NP (Figure 1A) showed visible cytopathic effect (c.p.e.) on the
ninth day post-transfection. Western blot analysis was done to
confirm the expression of HA and NP in 293 cells. Two distinct
polypeptide bands of approximate molecular weights 77 kDa and
50 kDa, representing the HA precursor (HA0) and a proteolytic
cleavage product (HA1), respectively, (Figure 1B) were observed in
the HAd-HA-NP infected 293 cell lysate. A single band at
approximate molecular weight of 56 kDa representing NP
(Figure 1C) was visible in the HAd-HA-NP infected 293 cell lysate.
Generation of HAd-primed mice having HAd neutralizing
antibodies
To mimic in a mouse model the preexisting immunity against
HAd5 observed in the majority of the human population, groups
of animals were inoculated i.n. or i.m. with a single dose of 10
7,
10
8,o r1 0
9 plaque forming units (p.f.u.) HAd-WT. Both i.n. and
i.m. primed groups showed a dose-dependent increase in the levels
of HAd-specific neutralizing antibody titers (Figure 2). As
expected, the highest HAd-specific neutralizing antibody titers in
i.n. inoculated HAd-primed groups were observed with a
10
9 p.f.u. dose of HAd-WT (2240) followed by 10
8 p.f.u. (1040)
and 10
7 p.f.u. (300) dose (Figure 2). Similarly, the i.m. primed
group receiving 10
9 p.f.u. of HAd-WT developed the highest titer
(3040) followed by 10
8 p.f.u. (1480) and 10
7 p.f.u. (520) dose
groups (Fig. 2). The i.m. primed groups resulted in the
development of higher levels of HAd-specific neutralizing antibody
titers compared to the i.n. primed groups.
Induction of humoral immune response in HAd-primed
mice immunized with HAd-HA-NP
Development of a robust HA-specific antibody response is an
important indicator of the immunogenicity and protective efficacy
of an influenza vaccine [21]. The i.n. or i.m. immunization of
Figure 1. Replication-defective HAd vector (HAd-HA-NP) expresses HA and NP of a H5N1 influenza virus in vector-infected cells. (A)
Diagrammatic representation of replication-deficient HAd vectors, HAd-DE1E3 [HAd5 with deleted E1 and E3 regions] and HAd-HA-NP [HAd-DE1E3
with hemaggluttinin (HA) and nucleoprotein (NP) gene from A/Vietnam/1203/04 (H5N1) influenza virus]. ITR, inverted terminal repeat; CMV,
cytomegalovirus immediate early promoter; pA, polyadenylation signal; MCMV, mouse cytomegalovirus immediate early promoter; SV40pA, simian
virus polyadenylation signal. (B and C) Expression of H5N1 HA and NP in 293 cells infected with HAd-HA-NP. Mock (PBS-infected), HAd-DE1E3-, or
HAd-HA-NP-infected 293 cells were harvested 48 h post-infection, and cell lysates were analyzed by Western blot using polyclonal serum against H5
HA or a NP-specific mouse monoclonal antibody.
doi:10.1371/journal.pone.0033428.g001
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ric mean (GM) hemagglutination inhibition (HI) titers (Table 1).
The 10
7 i.n. HAd-primed groups developed significantly high
serum HI titers compared to the vector control group by the i.n.
(120) or i.m. (160) routes of immunization with 10
8 p.f.u. of HAd-
HA-NP. Similarly, 10
7 i.m. HAd- primed groups developed
significantly higher (P#0.05) serum HI titers compared to the
vector control group by both i.m. (105) and i.n. (91) routes of
immunization with HAd-HA-NP. The serum HI titers in 10
7
HAd-primed groups (i.n. or i.m.) immunized with the vaccine were
1.5–2 fold lower than the naı ¨ve immunized groups indicating that
HAd-preexisting antibodies affected the induction of humoral
immune response following immunization with HAd-HA-NP. In
the 10
8 i.n. HAd-primed group, i.n. immunization with HAd-HA-
NP induced lower serum HI titers (22) compared to the group
immunized i.m. with HAd-HA-NP (80). Interestingly, an increase
in the vaccine dose by five-fold resulted in significant (P#0.05)
enhancement of serum HI titers in mice immunized either i.n. (91)
or i.m. (105). A similar trend was observed in the case of 10
8 i.m.
HAd-primed groups indicating that alternating the route of
priming and immunization or increasing the vaccine dose can
partially overcome the vector immunity.
In the 10
9 i.n. HAd-primed group, i.n. immunization with
HAd-HA-NP induced lower serum HI titers (22). Alternating with
the i.m. route of immunization resulted in slight improvement in
the HI titers (34). Increasing the vaccine dose by five-fold resulted
in further improvement in HI titers in mice immunized either i.n.
(52) or i.m. (80) indicating that the i.n.-induced (which mimics the
natural route of infection in humans) vector immunity can be
partially overcome by increasing the vaccine dose (P#0.05).
However, in the 10
9 i.m. HAd-primed groups immunized with
HAd-HA-NP, a HI titer of 30 was induced, and there were no
significant changes in the titers by either alternating the route of
vaccine inoculation or with an increased vaccine dose. These
results indicate that the levels of vector immunity induced by i.m.
priming with 10
9 p.f.u. of HAd5-WT negatively impact the
development of a humoral immune response against a HAd
vector-based vaccine.
Induction of cellular immune response in HAd-primed
mice immunized with HAd-HA-NP
Cell-mediated immunity (CMI) plays an important role in virus
clearance and thus contributes to the recovery from an influenza
infection [22,23]. As anticipated, the HAd-HA-NP vaccine elicited
significantly higher percentages of NP-147 epitope-specific CD8 T
cells in the naı ¨ve groups compared to the vector (HAd-DE1E3)
control group (Figure 3A & 3B). The percentages of NP-147
epitope-specific CD8 T cells in 10
7 HAd-primed groups (i.n. or
i.m.) was significantly higher than in vector control groups
following immunization with HAd-HA-NP by either the i.n. or
i.m. route. However, the percentages NP-147-specific CD8 T cells
were 1.5–2 fold lower in HAd-primed groups (i.n. or i.m.)
compared to naı ¨ve groups, suggesting that preexisting vector
immunity had a modest effect on the induction of CMI following
immunization with HAd-HA-NP (Figure 3A & 3B).
The percentages of NP-147 epitope-specific CD8 T cells in 10
8
HAd-primed groups were two-fold lower compared to the 10
7
HAd-primed groups (i.n. or i.m.) following immunization with
HAd-HA-NP by either route (Figure 3A & 3B). Interestingly,
increasing the vaccine dose by five-fold resulted in significantly
higher percentages of NP-147 epitope-specific CD8 T cells in the
10
8 HAd-primed groups compared to both 10
7 and 10
8 HAd-
primed groups receiving the lower dose (10
8 p.f.u.) of the vaccine.
As expected, a further increase in the level of preexisting vector
immunity led to a further decrease in the percentages of NP-147
epitope-specific CD8 T cells. Furthermore, an increase in the
vaccine dose by five-fold resulted in significantly higher percent-
ages of NP-147 epitope-specific CD8 T cells in the 10
9 i.n. primed
group compared to the 10
9 i.n. primed group receiving the lower
vaccine dose (10
8 p.f.u.). However, this increase was not noticeable
in the 10
9 i.m. primed group.
The functionality of HA-518 and NP-147-specific CD8 T cells
was assessed by enumerating interferon-c (IFN-c) expressing cells
by ELISpot assay. Significantly higher numbers of IFN-c-secreting
HA-518- and NP-147-specific CD8 T cells were detected in the
spleens from the naı ¨ve groups immunized i.n. or i.m. with HAd-
HA-NP compared to the vector control groups following
stimulation with the HA-518 (P#0.0001) or NP-147 (P#0.0001)
peptide, respectively (Figure 4A–D). In general, the number of
IFN-c-secreting HA-518- or NP-147-specific CD8 T cells in the
spleens of HAd-primed groups immunized with the vaccine were
lower compared to the naı ¨ve immunized groups, and a five-fold
increase in the vaccine dose resulted in an increase in the number
of IFN-c secreting HA-518- or NP-147-specific CD8 T cells in all
the primed groups except for the 10
9 i.m. primed groups
(Figure 4A–D). Overall, it seems that with the increase in
preexisting HAd5-neutralizing antibodies, there was a titer-
dependent decline in the CMI response which significantly
improved with an increase in the vaccine dose by five-fold. There
was excellent correlation between the ELISpot and NP pentamer
staining data.
Protection of HAd-primed mice immunized with HAd-
HA-NP following challenge with a reassortant H5N1
influenza virus
Unprimed mice immunized with HAd-HA-NP had lung viral
titers on day 3 post-challenge below the level of detection (1.5
Figure 2. Development of vector immunity in wild type (WT)
HAd5-primed animals. To induce HAd vector–specific immunity in
mice, 6–8 weeks old female BALB/c mice were primed intramuscularly
(i.m.) or intranasally (i.n.) with a single dose of 10
7,1 0
8,o r1 0
9 p.f.u. of
HAd-WT. The unprimed mice received PBS. Four weeks after priming,
mice were bled by retro-orbital puncture to evaluate the development
of HAd-specific neutralizing antibodies by virus neutralization assay.
Virus neutralization titers were the reciprocal of the highest serum
dilution that completely prevented the development of c.p.e. The error
bars represent Mean 6 SD from five animals/group: *, P#0.05;
***, P#0.005.
doi:10.1371/journal.pone.0033428.g002
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7 HAd-primed groups (i.n. or
i.m.) immunized with HAd-HA-NP had lung viral titers at or
below the level of detection (1.5 Log10 EID50/ml) indicating that
the preexisting vector immunity did not adversely impact the
protective efficacy. However, the 10
8 HAd-primed groups (i.n. or
i.m.) immunized with HAd-HA-NP by the same route that was
used for priming exhibited less efficient virus clearance from the
lungs. Interestingly, either using a different route of inoculation for
priming and vaccination or increasing the vaccine dose by five-fold
resulted in lung viral titers at or below the level of detection. In the
10
9 i.n. HAd-primed groups (i.n. or i.m.) immunized with HAd-
HA-NP by the same route that was used for priming, there was
only partial (approximately 2–4 logs) virus clearance. By changing
the route of priming and immunization, complete protection was
observed only in the group where the i.n. priming was followed by
a five-fold increase in the vaccine dose administered by either
route (i.m. or i.n.). Even a five-fold increase in the vaccine dose did
not yield complete protection in the 10
9 i.m. HAd-primed groups
immunized with HAd-HA-NP by either route (i.n. or i.m.)
suggesting that the level of preexisting vector-neutralizing antibody
titer could serve as an indicator for predicting the efficacy of Ad-
based vaccines.
Discussion
To meet the global vaccine demand in a pandemic, various egg-
independent vaccine strategies need to be explored to supplement
egg-dependent influenza vaccine approaches. Ad vector-based
influenza vaccines have been shown in clinical studies to be safe
and immunogenic in humans [24,25]. The strong innate and
adaptive immune responses induced by Ad vectors impart
adjuvant-like properties facilitating better immune responses
against the transgene product/s. However, several preclinical
studies have suggested that the presence of preexisting HAd-
specific neutralizing antibodies might inhibit the generation of
immune responses against the expressed immunogen [1,14,18]. In
the present study, we evaluated the role of preexisting HAd5-
specific neutralizing antibodies in inhibiting the immunogenicity
Table 1. Hemagglutination inhibition (HI) antibody titers before challenge and lung viral titers 3 days post-challenge with a
homologous H5N1 reassortant virus in HAd-HA-NP-immunized naı ¨ve and HAd-primed mice.
Preimmunization Immunization HI titers (GM) Log10EID50/ml ± S.D.
10
9 HAd-WT (i.n.) 5610
8 HAd-DE1E3 (i.n.) 10 6.560.1
10
7 HAd-WT (i.n.) 10
8 HAd-HA-NP (i.m.) 160 #1.5
10
7 HAd-WT (i.n.) 10
8 HAd-HA-NP (i.n.) 120 #1.5
10
8 HAd-WT (i.n.) 10
8 HAd-HA-NP (i.m.) 80 #1.5
10
8 HAd-WT (i.n.) 10
8 HAd-HA-NP (i.n.) 22 2.361
10
8 HAd-WT (i.n.) 5610
8 HAd-HA-NP (i.m.) 105 #1.5
10
8 HAd-WT (i.n.) 5610
8 HAd-HA-NP (i.n.) 91 #1.5
10
9 HAd-WT (i.n.) 10
8 HAd-HA-NP (i.m.) 34 2.760.5
10
9 HAd-WT (i.n.) 10
8 HAd-HA-NP (i.n.) 22 2.360.2
10
9 HAd-WT (i.n.) 5610
8 HAd-HA-NP (i.m.) 80 #1.5
10
9 HAd-WT (i.n.) 5610
8 HAd-HA-NP (i.n.) 52 #1.5
PBS (i.n.) 10
8 HAd-HA-NP (i.m.) 320 #1.5
PBS (i.n.) 10
8 HAd-HA-NP (i.n.) 183 #1.5
PBS (i.n.) 5610
8 HAd-HA-NP (i.m.) 485 #1.5
PBS (i.n.) 5610
8 HAd-HA-NP (i.n.) 278 #1.5
10
9 HAd-WT (i.m.) 5610
8 HAd-DE1E3 (i.n.) 10 6.560.1
10
7 HAd-WT (i.m.) 10
8 HAd-HA-NP (i.m.) 105 #1.5
10
7 HAd-WT (i.m.) 10
8 HAd-HA-NP (i.n.) 91 #1.5
10
8 HAd-WT (i.m.) 10
8 HAd-HA-NP (i.m.) 22 4.360.1
10
8 HAd-WT (i.m.) 10
8 HAd-HA-NP (i.n.) 60 #1.5
10
8 HAd-WT (i.m.) 5610
8 HAd-HA-NP (i.m.) 45 1.760.4
10
8 HAd-WT (i.m.) 5610
8 HAd-HA-NP (i.n.) 69 #1.5
10
9 HAd-WT (i.m.) 10
8 HAd-HA-NP (i.m.) 30 4.460.1
10
9 HAd-WT (i.m.) 10
8 HAd-HA-NP (i.n.) 10 4.060.1
10
9 HAd-WT (i.m.) 5610
8 HAd-HA-NP (i.m.) 30 2.860.5
10
9 HAd-WT (i.m.) 5610
8 HAd-HA-NP (i.n.) 34 3.260.1
Mice (10 animals/group) were inoculated i.m. or i.n. either with PBS (unprimed group) or with 10
7,1 0
8,o r1 0
9 p.f.u. of WT HAd5 (HAd-primed). Subsequently, naı ¨ve and
HAd-primed mice were immunized i.m. or i.n. twice at four week interval with HAd-HA-NP. HAd-primed mice inoculated with HAd-DE1E3 (vector control) served as
negative controls. Serum samples were obtained from all animals four weeks after the last immunization and analyzed by HI assay using a H5N1 reassortant virus and
horse red blood cells. The titers are shown as geometric mean values (GM). Four weeks after the last immunization, mice from each group were challenged with 100-
fold of 50% mouse infectious dose (MID50) of a H5N1 reassortant virus having HA and NA genes of A/Vietnam/1203/04 influenza virus. Three days post challenge mice
were euthanized, and the lungs were collected. The lung viral titers were determined to evaluate the protective efficacy of the vaccine. The detection limit of the lung
viral titer was $1.5 Log10 EID50/ml. HAd, human adenovirus; WT, wild type; i.m., intramuscular; i.n., intranasal.
doi:10.1371/journal.pone.0033428.t001
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mouse model. Low levels of vector immunity (,520 virus-
neutralization titer) did not seem to adversely affect the protective
vaccine efficacy, while further increases in vector immunity were
taken care of by using an alternate route of immunization or by an
increase in the vaccine dose. The importance of NP-specific CD4
T cells and non-neutralizing antibodies in the virus clearance was
not pursued in this study.
To mimic the natural exposure of HAd to the majority of
humans, we primed mice with HAd5 by the i.n. route to establish
the state of preexisting vector immunity since many HAd infect via
the mucosal route. The i.m. HAd5-primed groups represented the
development of HAd-specific immune responses following i.m.
immunization with a HAd vector-based vaccine. We attempted to
circumvent the inhibitory effect of high levels of preexisting vector
immunity by either a change in the route of vaccine inoculation or
an increase in the vaccine dose.
In the presence of preexisting neutralizing antibodies (300–520),
there was a modest decline in the levels of CMI and HI levels in
response to immunization with HAd-HA-NP. This level of
immune response was sufficient enough to provide excellent
protection against the challenge with a H5N1 reassortant virus.
There were lower levels of humoral and cellular immune responses
after the i.n. immunization compared to the i.m. immunization
which is consistent with earlier findings [11,26–28].
Further increase in the levels of vector-specific neutralizing
antibody response (1000–1480) resulted in a greater decline in
influenza virus-specific immune responses with the inhibition more
pronounced when the route of inoculation for Ad-priming and
influenza virus immunization were the same (e.g., i.n. and i.n., i.m.
and i.m.). This level of vector immunity could be overcome either
by changing the route of priming and immunization or by
increasing the vaccine dose by five-fold. To test the upper limit of
vector immunity that could be tolerated without adversely
Figure 3. NP-147 epitope-specific CD8+ T cells in naı ¨ve or HAd5-primed mice immunized with HAd-HA-NP. Naı ¨ve or HAd-primed mice
were immunized as described in the Materials and Methods. At four weeks after final immunization, animals were euthanized, and the spleens were
collected. Single cell suspensions were prepared by passage through screens, and 1610
6 cells were stained with a murine MHC-encoded allele k
d–
specific pentamer for immunodominant NP-147 epitope-conjugated with phycoerythrin (PE) and also with anti-CD8 antibody-conjugated with
allophycocyanin (APC) and anti-CD19 antibody-conjugated with flouro-isothiocyanin (FITC). Flow cytometeric analysis was done to identify the
number of NP-147-specific CD8+ T cells. Data were collected using BD FACSCanto II (BD Bioscience, CA) and FACSDiva software was used for analysis.
Data from five mice/groups are shown. (A) Percentage of NP-147-specific CD8+ T cells in intranasally primed groups. (B) Percentage of NP-147-specific
CD8 T cells in intramuscularly primed groups. The error bars represent Mean 6 SD from five animals/group: *, P#0.05; **, P#0.01; {, P#0.001.
doi:10.1371/journal.pone.0033428.g003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33428affecting the vaccine protective efficacy, the vector-specific
neutralizing antibody titer was raised to 2240 by i.n. priming
with high doses of HAd5. The inhibitory effect was partially
overcome by the five-fold increase in the vaccine dose, and the
resultant immune response was sufficient to provide complete
protection. Further increase in the level of vector-specific
neutralizing antibody titer to 3040 by i.m. priming with HAd5
only provided partial protection even in the groups receiving a
high vaccine dose.
Alternating the route of priming and immunization was
partially successful in overcoming vector immunity thus indicating
the potential role of the route of inoculation in developing the level
of humoral and CMI responses. It has been suggested that the
route of vaccination impacts the magnitude, phenotype and
trafficking of antigen-specific CD8 T cells in mice [29,30]. A HAd-
based HIV vaccine also showed some inhibition in eliciting
immunogen-specific immune responses in the presence of vector
immunity, however, this effect was minimized by increasing the
vaccine dose [31]. Nevertheless, in a clinical trial with a HAd-
based influenza vaccine, there were no strong correlations between
vector immunity levels and a decrease in vaccine efficacy [25].
The inhibitory effect of vector immunity was more pronounced for
the humoral immune response compared to the CMI response
which is consistent with previous reports [32–34]. Taken together,
our data clearly show that the magnitude of humoral and cellular
immune responses to Ad-vectored vaccine antigens depend upon
the levels of preexisting antibodies against the vector. However,
vector-specific immune responses can be overcome by increasing
the antigen dose or by administering antigen by a different route.
In conclusion, based on the present study alone, it will be difficult
to predict the range of the vector immunity in humans that can be
tolerated or overcome by either increasing the dose or changing
the route of administration of the HAd5 vector-based vaccines.
Nevertheless, the study does highlight the importance of exploring
these strategies in humans to improve the outcome of HAd5
vector-based vaccines.
Materials and Methods
Ethics Statement
The Purdue University Biosafety Committee and Animal Care
and Use Committee approved the protocol for all animal studies at
Purdue University, under the auspices of the Institutional Animal
Care and Use Committee (IACUC) #A3231-01 which is
supported by the American Association for Laboratory Animal
Science (AALAS). The 293 cell line was obtained commercially
from American Type Culture Collection (ATCC), and the 293Cre
cell line was obtained from Merck & Co. The BHH2C cell line
which was created in the PI’s laboratory used a combination of
commercially available cell lines, MDBK and 293. The use of all
human cell lines and the construction of BHH2C hybrid cell line
were with permission from the Purdue University Institutional
Review Boards (IRB) formed in accordance with federal
regulations. A Research Exemption was obtained for the use of
commercially available human cell lines. The IRBs are a unit of
the Human Research Protection Program (HRPP) which is housed
within the Office of Research Administration (ORA).
Cell lines and recombinant viruses
293 (human embryonic kidney cells expressing HAd5 E1 gene
products; obtained from ATCC) and 293Cre (293 cells that
constitutively expresses Cre-recombinase enzyme (a gift from Merck
Inc., Whitehouse Station, NJ) [35] were grown as monolayer cultures
in Eagle’s minimum essential medium (MEM) (Life Technologies,
Gaithersburg, MD) and supplemented with 10% reconstituted
bovine serum (Fetal Clone III; Hyclone,L o g a n ,V T )a n d5 0mg/ml
gentamycin. All constructs were purified by cesium chloride density-
gradient centrifugation and titrated by plaque assays on a hybrid cell
line using MDBK and 293 cell lines (BHH2C) [36] as described
previously [37]. The construction and propagation of replication
defective HAd-DE1E3 (HAd5 vector having deletions in the E1 and
E3 regions) has been previously described [11]. HAd5-WT virus was
purified by cesium chloride density-gradient centrifugation and
titrated by plaque assay on BHH2C cells.
Generation of replication deficient HAd-HA-NP vector
A Cre-recombinase-mediated site-specific recombination tech-
nique [20] was used to insert the full-length coding region of the
HA gene (with a modified polybasic site) of the A/Vietnam/1203/
04 (H5N1) influenza virus under the control of the CMV promoter
and BGH polyA. The polybasic cleavage site QRERRRKKRQG
present in the HA gene of A/Vietnam/1203/04 (H5N1) influenza
virus was modified to QRETRQG to reduce the rare possibility of
genetic exchange between the HA in HAd-HA-NP vaccine and a
circulating strains of influenza A virus. The full-length coding
region of NP gene of the A/Vietnam/1203/04 (H5N1) virus
under control of the murine CMV promoter and the SV40 polyA
was similarly inserted into the E1 region of the HAd genome. Both
genes in HAd-HA-NP were in the E1-parallel orientation. The
recombinant virus was plaque purified, and its genome was
analyzed by restriction enzyme digestions to confirm the presence
of HA and NP gene cassettes and the absence of any other major
deletion or insertion.
Western blot analysis
293 cells were mock-infected or infected with an empty vector
(HAd-DE1E3) or HAd-HA-NP at a multiplicity of infection (m.o.i.)
of 20 p.f.u. per cell. Cells were harvested 36 h post-infection, and
cell lysates were prepared and analyzed by Western blot [38] with
a polyclonal serum against H5 HA (obtained from Immunology
and Pathogenesis Branch, Influenza Division, Centers for Disease
Control and Prevention, Atlanta, GA, USA) and a monoclonal
antibody against NP (obtained from Immunology and Pathogen-
esis Branch, Influenza Division, Centers for Disease Control and
Prevention, Atlanta, GA, USA) to confirm the expression of HA
and NP proteins. Mock (PBS) or HAd-DE1E3 served as negative
controls.
Figure 4. ELISpot measurements of IFN-c expression in spleen cells of naı ¨ve or HAd5-primed mice immunized with HAd-HA-NP.
Naı ¨ve or HAd5-primed mice were immunized as described in the Materials and Methods. At four weeks after final immunization, animals were
euthanized, and the spleens were collected. Single cell suspensions were prepared by passage through screens, and 1610
6 cells were cultured in the
presence of HA-518 or NP-147 peptide on anti-interferon-c antibody-coated 96-well filter plates and developed according to an ELISpot protocol.
Splenocytes cultured in presence of phorbol myristate acetate (PMA) and ionomycin served as positive controls in each group. The ELISpot plates
were read using a Bioreader 5000 (BIOSYS, Miami, FL). (A) Number of IFN-c-secreting NP-147-specific CD8 T cells in intranasally (i.n.) primed groups. (B)
Number of IFN-c-secreting NP-147-specific CD8 T cells in intramuscularly (i.m.) primed groups. (C) Number of IFN-c-secreting HA-518-specific CD8 T
cells in i.n. primed groups. (D) Number of IFN-c-secreting HA-518-specific CD8 T cells in i.m. primed groups. The error bars represent Mean 6 SD from
five animals/group: *, P#0.05; **, P#0.01; ***, P#0.005; {, P#0.001; {, P#0.0001.
doi:10.1371/journal.pone.0033428.g004
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vaccine efficacy
6–8 week old female BALB/c mice (10 animals/group) were
inoculated by either the i.m. or i.n. route with a single dose of 10
7,1 0
8,
or 10
9 p.f.u. of HAd-WT. These groups were referred to as HAd-
primed groups. The unprimed (naı ¨ve) mice were similarly inoculated
with phosphate-buffered saline (PBS). Four weeks after priming, mice
were bled by retro-orbital puncture to evaluate the development of
HAd-specific neutralizing antibody titers. HAd-primed and naı ¨ve
(PBS-inoculated) mice were subsequently immunized twice (4 weeks
apart) with 1610
8 or 5610
8 p.f.u. of HAd-HA-NP vaccine by either
the i.m. or i.n. route. Additional groups of HAd-primed mice were
similarly immunized with 5610
8 p.f.u. of HAd-DE1E3 (vector
control) to serve as negative controls.
Four weeks after final immunization, blood samples were
collected through retro-orbital puncture to evaluate the develop-
ment of HA-specific antibodies. Five animals from each group were
euthanized to collect the spleen cells to evaluate the induction of
HA- and NP-specific CMI responses. The remaining mice from
each group were challenged with 100-fold of 50% mouse infectious
dose (MID50) of a reverse genetics derived A/Puerto Rico/8/
1934(H1N1) [PR8] containing HA and NA gene fragments of A/
Vietnam/1203/04 (H5N1) [VNH5N1-PR8/CDC-RG][24]. Since
this reassortant virus is not lethal and does not produce clinical
disease and weight loss in mice, protection efficacy was monitored
by viral clearance in the lungs. Three days post-challenge, mice
were euthanized, and the lungs were collected to determine viral
titers to evaluate protective efficacy. Briefly, thawed lung tissues
were homogenized in 1 ml of sterile PBS. These lung homogenates
were then titrated in 10-day-old embryonated eggs in a 10-fold
dilution, and positive eggs were identified by hemagglutination of
horse red blood cells with allantoic fluid. Values were expressed as
log10 EID50/ml 6 SEM. The limit of virus detection was set as 1.5
log10 EID50/ml [39]. The NP genes are fairly conserved between
A/Vietnam/1203-04 (in the Ad vector) and A/PR8/34 (the
backbone of the challenge virus); there is 93% identity at the
aminoacidleveland85%identityatthenucleotidelevel.One ofthe
major CD8 T cell epitopes (NP147) is 100% conserved in between
A/Vietnam/1203-04 and A/PR8/34.
Serological assays
HAd neutralizing serum antibody titers were determined as
previously described [13]. The virus neutralization titer was the
reciprocal of the highest serum dilution that completely prevented
the development of c.p.e. Pre-challenge serum samples were
analyzed for the presence of HI antibody titers using horse red
blood cells as described previously [40].
NP-specific pentamer staining
Splenocytes were isolated and stained with a murine MHC k
d–
specific pentamer for immunodominant NP-147 epitope (Proim-
mune Inc., Bradenton, FL) conjugated with phycoerythrin (PE) and
an anti-CD8 antibody conjugated with Allophycocyanin (APC)
(BD PharMingen, San Jose, CA.) as described previously [11]. B cells
were removed by staining splenocytes with anti-CD19 flouro-
isothiocyanin (FITC) and gating them out in analysis. Flow
cytometric analyses were done using BD FACSCantoII, (BD
Bioscience, San Jose, CA) to identify the percent NP-147 epitope-
specific CD8+ T cells among the total splenic CD8+ T cells.
ELISpot assay
96-well filter plates (Millipore, Bedford, MA) were coated with an
anti-mouse interferon gamma (IFN-c) antibody (BD Bioscience, San
Jose, CA) and incubated at 4uC overnight. Splenocytes (3.3610
5
to 1610
6 cells per well) from each mice were cultured in the
presence of HA-518 or NP-147 peptides in RPMI medium
(GIBCO, Grand Island, NY), supplemented with 10% reconstituted
fetal bovine serum for 60 h and developed according to an
ELISpot protocol [41]. Splenocytes cultured in the presence of
phorbol myristate acetate (PMA) and ionomycin (Sigma-Aldrich,
Inc., St. Louis, MO) served as positive control within each group.
Statistical analysis
Log-transformation of titer measurement was assessed by
Shapiro-Wilktest, found to be normally distributed and used for
the analysis using SAS 9.2. Tukey’s multiple comparison was used
for calculation of significance. The significance was set at P ,0.05.
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